{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:44:35Z","timestamp":1793835875824,"version":"4.6.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI167966"],"award-info":[{"award-number":["P01AI167966"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["DP1AI158186"],"award-info":[{"award-number":["DP1AI158186"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93022C00036"],"award-info":[{"award-number":["75N93022C00036"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Middle East respiratory syndrome coronavirus (MERS-CoV) was identified as a human pathogen in 2012 and causes ongoing sporadic infections and outbreak clusters. Despite case fatality rates (CFRs) of over 30% and considerable pandemic potential, a safe and efficacious vaccine has not been developed. Here we report the design, characterization, and preclinical evaluation of MERS-CoV antigens. Our lead candidate comprises a stabilized spike displayed on a self-assembling ferritin nanoparticle that can be produced from a high-expressing, stable cell pool. This vaccine elicits robust MERS-CoV pseudovirus and authentic virus neutralizing antibody titers in BALB\/c mice. Immunization of male non-human primates (NHPs) with one dose of Alhydrogel-adjuvanted vaccine elicited a\u2009&gt;\u200910\n                    <jats:sup>3<\/jats:sup>\n                    geometric mean titer of pseudovirus neutralizing antibodies that was boosted with a second dose. Sera from these NHPs exhibited cross-reactivity against spike-pseudotyped lentiviruses from MERS-CoV clades A, B, and C as well as a distant pangolin merbecovirus. In human DPP4 transgenic mice, immunization provided dose-dependent protection against MERS-CoV lethal challenge, and in an established alpaca challenge model using female alpacas, immunization fully protected against MERS-CoV infection. This MERS-CoV nanoparticle vaccine is a promising candidate for clinical advancement to protect at-risk individuals and for future use in a potential outbreak setting.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-68458-5","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T18:04:02Z","timestamp":1770314642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6408-9495","authenticated-orcid":false,"given":"Abigail E.","family":"Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9625-9986","authenticated-orcid":false,"given":"Hannah","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7399-411X","authenticated-orcid":false,"given":"Soyoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"O\u2019Rear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0500-146X","authenticated-orcid":false,"given":"Brian J.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8523-1528","authenticated-orcid":false,"given":"Daniel J.","family":"Stieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-1402","authenticated-orcid":false,"given":"Adam M.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0619-7487","authenticated-orcid":false,"given":"David M.","family":"Belnap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneliese","family":"Bruening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airn","family":"Hartwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0007-2226","authenticated-orcid":false,"given":"Kaitlin R.","family":"Sprouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Addetia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer N.","family":"Alshukairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Ahyong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristy S.","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6019-8675","authenticated-orcid":false,"given":"David","family":"Veesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7576-2881","authenticated-orcid":false,"given":"Richard","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Ledgerwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-9684","authenticated-orcid":false,"given":"Michael S.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payton A.-B.","family":"Weidenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad A.","family":"Palanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"68458_CR1","unstructured":"Middle East respiratory syndrome coronavirus - Kingdom of Saudi Arabia https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON569."},{"key":"68458_CR2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3390\/microorganisms8070991","volume":"8","author":"A Mostafa","year":"2020","unstructured":"Mostafa, A. et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science. Microorganisms 8, 991 (2020).","journal-title":"Microorganisms"},{"key":"68458_CR3","doi-asserted-by":"crossref","DOI":"10.1038\/srep21878","volume":"6","author":"VJ Munster","year":"2016","unstructured":"Munster, V. J. et al. Replication and shedding of MERS-CoV in Jamaican fruit bats (Artibeus jamaicensis). Sci. Rep. 6, 21878 (2016).","journal-title":"Sci. Rep."},{"key":"68458_CR4","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3201\/eid1911.131172","volume":"19","author":"ZA Memish","year":"2013","unstructured":"Memish, Z. A. et al. Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia. Emerg. Infect. Dis. 19, 1819\u20131823 (2013).","journal-title":"Emerg. Infect. Dis."},{"key":"68458_CR5","doi-asserted-by":"publisher","unstructured":"Anthony, S. J. et al. (2017). Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus. mBio 8, https:\/\/doi.org\/10.1128\/mbio.00373-17.","DOI":"10.1128\/mbio.00373-17"},{"key":"68458_CR6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s44197-025-00426-6","volume":"15","author":"JA Al-Tawfiq","year":"2025","unstructured":"Al-Tawfiq, J. A. & Memish, Z. A. Recurrent MERS-CoV Transmission in Saudi Arabia\u2013 Renewed Lessons in Healthcare Preparedness and Surveillance. J. Epidemiol. Glob. Health 15, 77 (2025).","journal-title":"J. Epidemiol. Glob. Health"},{"key":"68458_CR7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(19)33221-0","volume":"395","author":"ZA Memish","year":"2020","unstructured":"Memish, Z. A., Perlman, S., Van Kerkhove, M. D. & Zumla, A. Middle East respiratory syndrome.  Lancet 395, 1063\u20131077 (2020).","journal-title":"Lancet"},{"key":"68458_CR8","volume":"8","author":"Y Yuan","year":"2017","unstructured":"Yuan, Y. et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 8, 15092 (2017).","journal-title":"Nat. Commun."},{"key":"68458_CR9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41594-019-0334-7","volume":"26","author":"Y-J Park","year":"2019","unstructured":"Park, Y.-J. et al. Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. Nat. Struct. Mol. Biol. 26, 1151\u20131157 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"68458_CR10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2013.92","volume":"23","author":"N Wang","year":"2013","unstructured":"Wang, N. et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 23, 986\u2013993 (2013).","journal-title":"Cell Res."},{"key":"68458_CR11","doi-asserted-by":"crossref","first-page":"12262","DOI":"10.1073\/pnas.1608147113","volume":"113","author":"J-E Park","year":"2016","unstructured":"Park, J.-E. et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc. Natl. Acad. Sci. USA 113, 12262\u201312267 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68458_CR12","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1073\/pnas.1510199112","volume":"112","author":"D Corti","year":"2015","unstructured":"Corti, D. et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc. Natl. Acad. Sci. USA 112, 10473\u201310478 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68458_CR13","first-page":"e02002","volume":"92","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. J. Virol. 92, e02002\u2013e02017 (2018).","journal-title":"J. Virol."},{"key":"68458_CR14","doi-asserted-by":"publisher","unstructured":"Addetia, A. et al. Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans. Cell Rep. 43, https:\/\/doi.org\/10.1016\/j.celrep.2024.114530 (2024).","DOI":"10.1016\/j.celrep.2024.114530"},{"key":"68458_CR15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","volume":"176","author":"AC Walls","year":"2019","unstructured":"Walls, A. C. et al. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. Cell 176, 1026\u20131039.e15 (2019).","journal-title":"Cell"},{"key":"68458_CR16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.07.015","volume":"133","author":"Q Wang","year":"2016","unstructured":"Wang, Q., Wong, G., Lu, G., Yan, J. & Gao, G. F. MERS-CoV spike protein: Targets for vaccines and therapeutics. Antivir. Res. 133, 165\u2013177 (2016).","journal-title":"Antivir. Res."},{"key":"68458_CR17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"68458_CR18","volume":"43","author":"CW Chao","year":"2024","unstructured":"Chao, C. W. et al. Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV. Cell Rep. 43, 115036 (2024).","journal-title":"Cell Rep."},{"key":"68458_CR19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/14760584.2020.1813574","volume":"19","author":"N Zhang","year":"2020","unstructured":"Zhang, N., Shang, J., Li, C., Zhou, K. & Du, L. An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies. Expert Rev. Vaccines 19, 817\u2013829 (2020).","journal-title":"Expert Rev. Vaccines"},{"key":"68458_CR20","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S2666-5247(21)00193-2","volume":"3","author":"M Bosaeed","year":"2022","unstructured":"Bosaeed, M. et al. Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.  Lancet Microbe 3, e11\u2013e20 (2022).","journal-title":"Lancet Microbe"},{"key":"68458_CR21","doi-asserted-by":"publisher","unstructured":"Weskamm, L. M. et al. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. CR Med 3, https:\/\/doi.org\/10.1016\/j.xcrm.2022.100685 (2022).","DOI":"10.1016\/j.xcrm.2022.100685"},{"key":"68458_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31557-0","volume":"13","author":"A Fathi","year":"2022","unstructured":"Fathi, A. et al. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome. Nat. Commun. 13, 4182 (2022).","journal-title":"Nat. Commun."},{"key":"68458_CR23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"K Modjarrad","year":"2019","unstructured":"Modjarrad, K. et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.  Lancet Infect. Dis. 19, 1013\u20131022 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"68458_CR24","doi-asserted-by":"publisher","unstructured":"Raadsen, M. P. et al. Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial. The Lancet Infectious Diseases. https:\/\/doi.org\/10.1016\/S1473-3099(24)00423-7 (2024).","DOI":"10.1016\/S1473-3099(24)00423-7"},{"key":"68458_CR25","doi-asserted-by":"publisher","unstructured":"Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. USA. 114, https:\/\/doi.org\/10.1073\/pnas.1707304114 (2017).","DOI":"10.1073\/pnas.1707304114"},{"key":"68458_CR26","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"68458_CR27","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"C-L Hsieh","year":"2020","unstructured":"Hsieh, C.-L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"68458_CR28","volume":"13","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. Cryoelectron microscopy structures of a human neutralizing antibody bound to MERS-CoV spike glycoprotein. Front Microbiol 13, 988298 (2022).","journal-title":"Front Microbiol"},{"key":"68458_CR29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/acscentsci.0c01405","volume":"7","author":"AE Powell","year":"2021","unstructured":"Powell, A. E. et al. A Single Immunization With Spike-functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. ACS Cent. Sci. 7, 183\u2013199 (2021).","journal-title":"ACS Cent. Sci."},{"key":"68458_CR30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-60250-1","volume":"16","author":"S De Cae","year":"2025","unstructured":"De Cae, S. et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base. Nat. Commun. 16, 5040 (2025).","journal-title":"Nat. Commun."},{"key":"68458_CR31","volume":"1","author":"CR Zamecnik","year":"2020","unstructured":"Zamecnik, C. R. et al. ReScan, a multiplex diagnostic pipeline, pans human sera for SARS-CoV-2 antigens. Cell Rep. Med. 1, 100123 (2020).","journal-title":"Cell Rep. Med."},{"key":"68458_CR32","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4250","volume":"370","author":"E Shrock","year":"2020","unstructured":"Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science 370, eabd4250 (2020).","journal-title":"Science"},{"key":"68458_CR33","volume":"34","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Cell Rep. 34, 108915 (2021).","journal-title":"Cell Rep."},{"key":"68458_CR34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cmdc.201200487","volume":"8","author":"PM Moyle","year":"2013","unstructured":"Moyle, P. M. & Toth, I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 8, 360\u2013376 (2013).","journal-title":"ChemMedChem"},{"key":"68458_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","volume":"120","author":"CP Karch","year":"2016","unstructured":"Karch, C. P. & Burkhard, P. Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem Pharm. 120, 1\u201314 (2016).","journal-title":"Biochem Pharm."},{"key":"68458_CR36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2008.04.036","volume":"364","author":"Y Perrie","year":"2008","unstructured":"Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E. & Bramwell, V. W. Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens. Int. J. Pharmaceutics 364, 272\u2013280 (2008).","journal-title":"Int. J. Pharmaceutics"},{"key":"68458_CR37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","volume":"499","author":"M Kanekiyo","year":"2013","unstructured":"Kanekiyo, M. et al. Self-Assembling Influenza Nanoparticle Vaccines Elicit Broadly Neutralizing H1N1 Antibodies. Nature 499, 102\u2013106 (2013).","journal-title":"Nature"},{"key":"68458_CR38","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo, M. et al. Rational design of an epstein-barr virus vaccine targeting the receptor-binding site. Cell 162, 1090\u20131100 (2015).","journal-title":"Cell"},{"key":"68458_CR39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","volume":"53","author":"Y Kato","year":"2020","unstructured":"Kato, Y. et al. Multifaceted effects of antigen valency on b cell response composition and differentiation in vivo. Immunity 53, 548\u2013563.e8 (2020).","journal-title":"Immunity"},{"key":"68458_CR40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","volume":"14","author":"J L\u00f3pez-Sagaseta","year":"2015","unstructured":"L\u00f3pez-Sagaseta, J., Malito, E., Rappuoli, R. & Bottomley, M. J. Self-assembling protein nanoparticles in the design of vaccines. Comput Struct. Biotechnol. J. 14, 58\u201368 (2015).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"68458_CR41","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367\u20131382.e17 (2020).","journal-title":"Cell"},{"key":"68458_CR42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jmb.2009.04.078","volume":"390","author":"KJ Cho","year":"2009","unstructured":"Cho, K. J. et al. The Crystal Structure of Ferritin from Helicobacter pylori Reveals Unusual Conformational Changes for Iron Uptake. J. Mol. Biol. 390, 83\u201398 (2009).","journal-title":"J. Mol. Biol."},{"key":"68458_CR43","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S2666-5247(23)00410-X","volume":"5","author":"BLO Shepherd","year":"2024","unstructured":"Shepherd, B. L. O. et al. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.  Lancet Microbe 5, e581\u2013e593 (2024).","journal-title":"Lancet Microbe"},{"key":"68458_CR44","volume":"14","author":"MG Joyce","year":"2021","unstructured":"Joyce, M. G. et al. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Sci. Transl. Med. 14, eabi5735 (2021).","journal-title":"Sci. Transl. Med."},{"key":"68458_CR45","volume":"14","author":"PA-B Weidenbacher","year":"2023","unstructured":"Weidenbacher, P. A.-B. et al. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nat. Commun. 14, 2149 (2023).","journal-title":"Nat. Commun."},{"key":"68458_CR46","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110143","volume":"37","author":"MG Joyce","year":"2021","unstructured":"Joyce, M. G. et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 37, 110143 (2021).","journal-title":"Cell Rep."},{"key":"68458_CR47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41591-021-01660-8","volume":"28","author":"KV Houser","year":"2022","unstructured":"Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med 28, 383\u2013391 (2022).","journal-title":"Nat. Med"},{"key":"68458_CR48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade4790","volume":"15","author":"AT Widge","year":"2023","unstructured":"Widge, A. T. et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci. Transl. Med 15, eade4790 (2023).","journal-title":"Sci. Transl. Med"},{"key":"68458_CR49","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/bit.27742","volume":"118","author":"S Rajendran","year":"2021","unstructured":"Rajendran, S. et al. Accelerating and de-risking CMC development with transposon-derived manufacturing cell lines. Biotechnol. Bioeng. 118, 2301\u20132311 (2021).","journal-title":"Biotechnol. Bioeng."},{"key":"68458_CR50","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1021\/acs.jproteome.1c00323","volume":"20","author":"BG Cho","year":"2021","unstructured":"Cho, B. G. et al. Direct comparison of N- glycans and their isomers derived from spike glycoprotein 1 of MERS-CoV, SARS-CoV-1, and SARS-CoV-2. J. Proteome Res. 20, 4357\u20134365 (2021).","journal-title":"J. Proteome Res."},{"key":"68458_CR51","volume":"11","author":"Y Watanabe","year":"2020","unstructured":"Watanabe, Y. et al. Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nat. Commun. 11, 2688 (2020).","journal-title":"Nat. Commun."},{"key":"68458_CR52","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2022.340394","volume":"1230","author":"X Dong","year":"2022","unstructured":"Dong, X., Li, X., Chen, C., Zhang, X. & Liang, X. Systematic analysis and comparison of O-glycosylation of five recombinant spike proteins in \u03b2-coronaviruses. Anal. Chim. Acta 1230, 340394 (2022).","journal-title":"Anal. Chim. Acta"},{"key":"68458_CR53","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/cr.2015.113","volume":"25","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 25, 1237\u20131249 (2015).","journal-title":"Cell Res."},{"key":"68458_CR54","volume":"6","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 6, 7712 (2015).","journal-title":"Nat. Commun."},{"key":"68458_CR55","doi-asserted-by":"publisher","unstructured":"Jiang, L. et al. Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein. Sci. Transl. Med. 6. https:\/\/doi.org\/10.1126\/scitranslmed.3008140 (2014).","DOI":"10.1126\/scitranslmed.3008140"},{"key":"68458_CR56","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/infdis\/jix209","volume":"215","author":"Z Chen","year":"2017","unstructured":"Chen, Z. et al. Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.  J. Infect. Dis. 215, 1807\u20131815 (2017).","journal-title":"J. Infect. Dis."},{"key":"68458_CR57","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83710","volume":"12","author":"RP Silva","year":"2023","unstructured":"Silva, R. P. et al. Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses. eLife 12, e83710 (2023).","journal-title":"eLife"},{"key":"68458_CR58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41594-022-00735-5","volume":"29","author":"SM Costello","year":"2022","unstructured":"Costello, S. M. et al. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Nat. Struct. Mol. Biol. 29, 229\u2013238 (2022).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"68458_CR59","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41589-022-01140-1","volume":"18","author":"PA-B Weidenbacher","year":"2022","unstructured":"Weidenbacher, P. A.-B. et al. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Nat. Chem. Biol. 18, 1270\u20131276 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"68458_CR60","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/v12050513","volume":"12","author":"KHD Crawford","year":"2020","unstructured":"Crawford, K. H. D. et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12, 513 (2020).","journal-title":"Viruses"},{"key":"68458_CR61","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3201\/eid2012.141280","volume":"20","author":"DR Adney","year":"2014","unstructured":"Adney, D. R. et al. Replication and Shedding of MERS-CoV in Upper Respiratory Tract of Inoculated Dromedary Camels. Emerg. Infect. Dis. 20, 1999\u20132005 (2014).","journal-title":"Emerg. Infect. Dis."},{"key":"68458_CR62","doi-asserted-by":"crossref","first-page":"20574","DOI":"10.2807\/1560-7917.ES2013.18.36.20574","volume":"18","author":"RA Perera","year":"2013","unstructured":"Perera, R. A. et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Eurosurveillance 18, 20574 (2013).","journal-title":"Eurosurveillance"},{"key":"68458_CR63","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2147\/IJWH.S50365","volume":"6","author":"R De Vincenzo","year":"2014","unstructured":"De Vincenzo, R., Conte, C., Ricci, C., Scambia, G. & Capelli, G. Long-term efficacy and safety of human papillomavirus vaccination. Int. J. Women\u2019s. Health 6, 999\u20131010 (2014).","journal-title":"Int. J. Women\u2019s. Health"},{"key":"68458_CR64","volume":"118","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z. et al. Phenotypic and genetic characterization of MERS coronaviruses from Africa to understand their zoonotic potential. Proc. Natl. Acad. Sci. USA 118, e2103984118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68458_CR65","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.cell.2023.01.019","volume":"186","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. A bat MERS-like coronavirus circulates in pangolins and utilizes human DPP4 and host proteases for cell entry. Cell 186, 850\u2013863.e16 (2023).","journal-title":"Cell"},{"key":"68458_CR66","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/infdis\/jit180","volume":"208","author":"JE Ledgerwood","year":"2013","unstructured":"Ledgerwood, J. E. et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J. Infect. Dis. 208, 418\u2013422 (2013).","journal-title":"J. Infect. Dis."},{"key":"68458_CR67","doi-asserted-by":"crossref","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","volume":"7","author":"C-T Tseng","year":"2012","unstructured":"Tseng, C.-T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLOS ONE 7, e35421 (2012).","journal-title":"PLOS ONE"},{"key":"68458_CR68","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3201\/2206.160192","volume":"22","author":"DR Adney","year":"2016","unstructured":"Adney, D. R., Bielefeldt-Ohmann, H., Hartwig, A. E. & Bowen, R. A. Infection, replication, and transmission of middle east respiratory syndrome coronavirus in Alpacas. Emerg. Infect. Dis. 22, 1031\u20131037 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"68458_CR69","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., S. Arunachalam, P. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"68458_CR70","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.immuni.2024.03.015","volume":"57","author":"EC Lavelle","year":"2024","unstructured":"Lavelle, E. C. & McEntee, C. P. Vaccine adjuvants: Tailoring innate recognition to send the right message. Immunity 57, 772\u2013789 (2024).","journal-title":"Immunity"},{"key":"68458_CR71","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","volume":"29","author":"D Smirnov","year":"2011","unstructured":"Smirnov, D., Schmidt, J. J., Capecchi, J. T. & Wightman, P. D. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29, 5434\u20135442 (2011).","journal-title":"Vaccine"},{"key":"68458_CR72","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1128\/IAI.71.12.6915-6920.2003","volume":"71","author":"DJ Lefeber","year":"2003","unstructured":"Lefeber, D. J. et al. Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related to Streptococcus pneumoniae Type 3. Infect. Immun. 71, 6915\u20136920 (2003).","journal-title":"Infect. Immun."},{"key":"68458_CR73","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2017.06.005","volume":"47","author":"AS McKee","year":"2017","unstructured":"McKee, A. S. & Marrack, P. Old and new adjuvants. Curr. Opin. Immunol. 47, 44\u201351 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"68458_CR74","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3390\/vaccines9121490","volume":"9","author":"M Ghattas","year":"2021","unstructured":"Ghattas, M., Dwivedi, G., Lavertu, M. & Alameh, M.-G. Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines 9, 1490 (2021).","journal-title":"Vaccines"},{"key":"68458_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-021-02441-2","volume":"4","author":"MJ Carrasco","year":"2021","unstructured":"Carrasco, M. J. et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun. Biol. 4, 1\u201315 (2021).","journal-title":"Commun. Biol."},{"key":"68458_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44298-024-00048-y","volume":"2","author":"N van Doremalen","year":"2024","unstructured":"van Doremalen, N. et al. Transmission dynamics of MERS-CoV in a transgenic human DPP4 mouse model. npj Viruses 2, 1\u20138 (2024).","journal-title":"npj Viruses"},{"key":"68458_CR77","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2017.02.012","volume":"35","author":"CM Coleman","year":"2017","unstructured":"Coleman, C. M. et al. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine 35, 1586\u20131589 (2017).","journal-title":"Vaccine"},{"key":"68458_CR78","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.vaccine.2014.04.016","volume":"32","author":"CM Coleman","year":"2014","unstructured":"Coleman, C. M. et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32, 3169\u20133174 (2014).","journal-title":"Vaccine"},{"key":"68458_CR79","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1016\/j.vaccine.2018.04.082","volume":"36","author":"S-Y Jung","year":"2018","unstructured":"Jung, S.-Y. et al. Heterologous prime\u2013boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine 36, 3468\u20133476 (2018).","journal-title":"Vaccine"},{"key":"68458_CR80","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41661-4","volume":"14","author":"GB Hutchinson","year":"2023","unstructured":"Hutchinson, G. B. et al. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera. Nat. Commun. 14, 6195 (2023).","journal-title":"Nat. Commun."},{"key":"68458_CR81","doi-asserted-by":"crossref","first-page":"301ra132","DOI":"10.1126\/scitranslmed.aac7462","volume":"7","author":"K Muthumani","year":"2015","unstructured":"Muthumani, K. et al. A synthetic consensus anti\u2013spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci. Transl. Med 7, 301ra132 (2015).","journal-title":"Sci. Transl. Med"},{"key":"68458_CR82","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba8399","volume":"6","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen, N. et al. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci. Adv. 6, eaba8399 (2020).","journal-title":"Sci. Adv."},{"key":"68458_CR83","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.cell.2024.12.032","volume":"188","author":"Y-J Park","year":"2025","unstructured":"Park, Y.-J. et al. Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses. Cell 188, 1711\u20131728.e21 (2025).","journal-title":"Cell"},{"key":"68458_CR84","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1021\/acs.jproteome.2c00145","volume":"21","author":"AM Frankenfield","year":"2022","unstructured":"Frankenfield, A. M., Ni, J., Ahmed, M. & Hao, L. Protein Contaminants Matter: Building Universal Protein Contaminant Libraries for DDA and DIA Proteomics. J. Proteome Res. 21, 2104\u20132113 (2022).","journal-title":"J. Proteome Res"},{"key":"68458_CR85","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jsb.2005.07.007","volume":"152","author":"DN Mastronarde","year":"2005","unstructured":"Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36\u201351 (2005).","journal-title":"J. Struct. Biol."},{"key":"68458_CR86","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jsb.2012.09.006","volume":"180","author":"SHW Scheres","year":"2012","unstructured":"Scheres, S. H. W. RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519\u2013530 (2012).","journal-title":"J. Struct. Biol."},{"key":"68458_CR87","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"68458_CR88","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","volume":"192","author":"A Rohou","year":"2015","unstructured":"Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216\u2013221 (2015).","journal-title":"J. Struct. Biol."},{"key":"68458_CR89","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/s41592-019-0575-8","volume":"16","author":"T Bepler","year":"2019","unstructured":"Bepler, T. et al. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. Nat. Methods 16, 1153\u20131160 (2019).","journal-title":"Nat. Methods"},{"key":"68458_CR90","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jmb.2011.11.010","volume":"415","author":"SHW Scheres","year":"2012","unstructured":"Scheres, S. H. W. A Bayesian View on Cryo-EM Structure Determination. J. Mol. Biol. 415, 406\u2013418 (2012).","journal-title":"J. Mol. Biol."},{"key":"68458_CR91","volume":"8","author":"J-L Chen","year":"2022","unstructured":"Chen, J.-L. et al. Self-assembling peptide nanofiber HIV vaccine elicits robust vaccine-induced antibody functions and modulates Fc glycosylation. Sci. Adv. 8, eabq0273 (2022).","journal-title":"Sci. Adv."},{"key":"68458_CR92","doi-asserted-by":"crossref","first-page":"15214","DOI":"10.1073\/pnas.1407087111","volume":"111","author":"JK Millet","year":"2014","unstructured":"Millet, J. K. & Whittaker, G. R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl. Acad. Sci. USA 111, 15214\u201315219 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68458_CR93","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41586-022-05513-3","volume":"612","author":"Q Xiong","year":"2022","unstructured":"Xiong, Q. et al. Close relatives of MERS-CoV in bats use ACE2 as their functional receptors. Nature 612, 748\u2013757 (2022).","journal-title":"Nature"},{"key":"68458_CR94","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1128\/JVI.02519-09","volume":"84","author":"Y Kaname","year":"2010","unstructured":"Kaname, Y. et al. Acquisition of complement resistance through incorporation of CD55\/decay-accelerating factor into viral particles bearing baculovirus GP64. J. Virol. 84, 3210\u20133219 (2010).","journal-title":"J. Virol."},{"key":"68458_CR95","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41586-021-03925-1","volume":"598","author":"FA Lempp","year":"2021","unstructured":"Lempp, F. A. et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature 598, 342\u2013347 (2021).","journal-title":"Nature"},{"key":"68458_CR96","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4269\/ajtmh.2007.76.310","volume":"76","author":"NM Nemeth","year":"2007","unstructured":"Nemeth, N. M. & Bowen, R. A. Dynamics of passive immunity to West Nile virus in domestic chickens (Gallus gallus domesticus). Am. J. Trop. Med Hyg. 76, 310\u2013317 (2007).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"68458_CR97","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1128\/JVI.78.17.9007-9015.2004","volume":"78","author":"T Giroglou","year":"2004","unstructured":"Giroglou, T. et al. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus s protein. J. Virol. 78, 9007\u20139015 (2004).","journal-title":"J. Virol."},{"key":"68458_CR98","doi-asserted-by":"crossref","first-page":"e76469","DOI":"10.1371\/journal.pone.0076469","volume":"8","author":"Z Qian","year":"2013","unstructured":"Qian, Z., Dominguez, S. R. & Holmes, K. V. Role of the spike glycoprotein of human middle east respiratory syndrome coronavirus (MERS-CoV) in Virus entry and syncytia formation. PLOS ONE 8, e76469 (2013).","journal-title":"PLOS ONE"},{"key":"68458_CR99","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68458-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68458-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68458-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:03:30Z","timestamp":1771391010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68458-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68458"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68458-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.E.P., S.P., J.O., J.E.L., P.A.W., and B.A.P. are listed as inventors on US patent application 63\/587,130, entitled \u201cEngineered Middle East Respiratory Syndrome Proteins and Related Methods\u201d which discloses subject matter described in this paper. A.E.P., H.C., J.L.C., J.O., B.J.F., D.J.S., A.M.W., J.E.L., P.A.W., and B.A.P. are employees of and may hold shares in Vaccine Company, Inc. S.P., V.A., C.S.D., and M.S.K. are former employees of Vaccine Company, Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1750"}}